<PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">39364568</PMID><DateRevised><Year>2024</Year><Month>10</Month><Day>04</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1468-1331</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2024</Year><Month>Oct</Month><Day>04</Day></PubDate></JournalIssue><Title>European journal of neurology</Title><ISOAbbreviation>Eur J Neurol</ISOAbbreviation></Journal><ArticleTitle>Immune triggers preceding neuralgic amyotrophy.</ArticleTitle><Pagination><StartPage>e16462</StartPage><MedlinePgn>e16462</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1111/ene.16462</ELocationID><Abstract><AbstractText Label="BACKGROUND AND PURPOSE" NlmCategory="OBJECTIVE">Infections and vaccinations have been identified as potential immunological triggers of neuralgic amyotrophy (NA), but the exact type and frequency of the preceding agents is unknown.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">This was a multicentre, prospective, observational, matched case-control study. NA was diagnosed by neuromuscular experts according to validated clinical criteria and electrodiagnostic studies. Clinical data and biological samples of NA patients were collected within 90 days from disease onset between June 2018 and December 2023. All NA patients were asked about prior infection and vaccination in the month before disease onset. Serological tests for hepatitis E virus, human immunodeficiency virus, severe acute respiratory syndrome coronavirus 2, Epstein-Barr virus, cytomegalovirus, parvovirus B19, varicella-zoster virus, Borrelia burgdorferi, Mycoplasma pneumoniae and Bartonella henselae were performed in a central laboratory. Each case was matched with a healthy control for age, sex, place of residence and time of blood collection.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Fifty-seven patients and corresponding controls were included. The mean age was 45 years for both groups. NA onset was preceded by a symptomatic infectious trigger confirmed by microbiological tests in 15/57 (26.3%) patients. Coronavirus disease 2019 vaccination was considered a potential trigger in 7/57 (12.3%) subjects. An acute viral infection was associated with a bilateral involvement of the brachial plexus (p = 0.003, Cramèr's V = 0.43).</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Confirmed immune triggers (infection or vaccination) preceded disease onset in 22/57 (38.6%) NA cases. We suggest to test NA patients in the acute phase for intracellular antigens, especially in the case of concomitant bilateral involvement and hepatitis.</AbstractText><CopyrightInformation>© 2024 The Author(s). European Journal of Neurology published by John Wiley &amp; Sons Ltd on behalf of European Academy of Neurology.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Sparasci</LastName><ForeName>Davide</ForeName><Initials>D</Initials><Identifier Source="ORCID">0000-0002-6190-1633</Identifier><AffiliationInfo><Affiliation>Department of Neurology, Neurocenter of Southern Switzerland EOC, Lugano, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schilg-Hafer</LastName><ForeName>Lenka</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Neurology, Cantonal Hospital, St Gallen, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schreiner</LastName><ForeName>Bettina</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Neurology, University and Hospital Zurich, Zurich, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Scheidegger</LastName><ForeName>Olivier</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Department of Neurology, Inselspital, Bern University Hospital and University of Bern, Bern, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Peyer</LastName><ForeName>Anne-Kathrin</ForeName><Initials>AK</Initials><AffiliationInfo><Affiliation>Department of Neurology, University Hospital and University of Basel, Basel, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lascano</LastName><ForeName>Agustina Maria</ForeName><Initials>AM</Initials><Identifier Source="ORCID">0000-0001-7572-8811</Identifier><AffiliationInfo><Affiliation>Neurology Division, Department of Clinical Neuroscience, University Hospitals of Geneva and Faculty of Medicine, University of Geneva, Geneva, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vicino</LastName><ForeName>Alex</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0001-6420-8124</Identifier><AffiliationInfo><Affiliation>Nerve-Muscle Unit, Neurology Service, Department of Clinical Neurosciences, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Décard</LastName><ForeName>Bernhard Friedrich</ForeName><Initials>BF</Initials><AffiliationInfo><Affiliation>Cantonal Hospital, Lucerne, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tsouni</LastName><ForeName>Pinelopi</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Neurology, Hôpital du Valais, Sion, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Humm</LastName><ForeName>Andrea Monika</ForeName><Initials>AM</Initials><AffiliationInfo><Affiliation>Neurology Unit, Department of Medicine, HFR Fribourg Cantonal Hospital, Fribourg, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pianezzi</LastName><ForeName>Enea</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Laboratory of Microbiology EOC, Bellinzona, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zezza</LastName><ForeName>Giulia</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Laboratory of Microbiology EOC, Bellinzona, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hundsberger</LastName><ForeName>Thomas</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Neurology, Cantonal Hospital, St Gallen, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dietmann</LastName><ForeName>Anelia</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0002-8949-0645</Identifier><AffiliationInfo><Affiliation>Department of Neurology, Inselspital, Bern University Hospital and University of Bern, Bern, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jung</LastName><ForeName>Hans H</ForeName><Initials>HH</Initials><AffiliationInfo><Affiliation>Department of Neurology, University and Hospital Zurich, Zurich, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kuntzer</LastName><ForeName>Thierry</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Nerve-Muscle Unit, Neurology Service, Department of Clinical Neurosciences, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wilder-Smith</LastName><ForeName>Einar</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Neurology, Inselspital, Bern University Hospital and University of Bern, Bern, Switzerland.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Cantonal Hospital, Lucerne, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Martinetti-Lucchini</LastName><ForeName>Gladys</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Laboratory of Microbiology EOC, Bellinzona, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Petrini</LastName><ForeName>Orlando</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>University of Applied Sciences and Arts of Southern Switzerland, Bellinzona, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fontana</LastName><ForeName>Stefano</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Blood Transfusion Service SRC Southern Switzerland, Lugano, Switzerland.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Interregional Blood Transfusion SRC, Bern, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gowland</LastName><ForeName>Peter</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Interregional Blood Transfusion SRC, Bern, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Niederhauser</LastName><ForeName>Christoph</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Interregional Blood Transfusion SRC, Bern, Switzerland.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute for Infectious Diseases, University of Bern, Bern, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gobbi</LastName><ForeName>Claudio</ForeName><Initials>C</Initials><Identifier Source="ORCID">0000-0002-7554-0664</Identifier><AffiliationInfo><Affiliation>Department of Neurology, Neurocenter of Southern Switzerland EOC, Lugano, Switzerland.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Faculty of Biomedical Sciences, Università della Svizzera Italiana, Lugano, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ripellino</LastName><ForeName>Paolo</ForeName><Initials>P</Initials><Identifier Source="ORCID">0000-0002-8662-9656</Identifier><AffiliationInfo><Affiliation>Department of Neurology, Neurocenter of Southern Switzerland EOC, Lugano, Switzerland.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Faculty of Biomedical Sciences, Università della Svizzera Italiana, Lugano, Switzerland.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><Agency>Baasch-Medicus Stiftung, Zurich</Agency><Country /></Grant><Grant><Agency>Neuromuscular Research Association Basel</Agency><Country /></Grant><Grant><Agency>Foundation for the Advancement of Neurology, Lausanne</Agency><Country /></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>10</Month><Day>04</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Eur J Neurol</MedlineTA><NlmUniqueID>9506311</NlmUniqueID><ISSNLinking>1351-5101</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Parsonage–Turner syndrome</Keyword><Keyword MajorTopicYN="N">immune trigger</Keyword><Keyword MajorTopicYN="N">infection</Keyword><Keyword MajorTopicYN="N">neuralgic amyotrophy</Keyword><Keyword MajorTopicYN="N">vaccination</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>6</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>4</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>8</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>4</Day><Hour>8</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>4</Day><Hour>8</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>4</Day><Hour>4</Hour><Minute>42</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39364568</ArticleId><ArticleId IdType="doi">10.1111/ene.16462</ArticleId></ArticleIdList><ReferenceList><Title>REFERENCES</Title><Reference><Citation>van Alfen N, van Engelen BGM. The clinical spectrum of neuralgic amyotrophy in 246 cases. Brain. 2006;129(2):438‐450.</Citation></Reference><Reference><Citation>van Alfen N, van Eijk JJJ, Ennik T, et al. Incidence of neuralgic amyotrophy (Parsonage Turner syndrome) in a primary care setting—a prospective cohort study. PLoS One. 2015;10(5):e0128361. doi:10.1371/journal.pone.0128361</Citation></Reference><Reference><Citation>van Eijk JJJ, Groothuis JT, van Alfen N. Neuralgic amyotrophy: an update on diagnosis, pathophysiology, and treatment. Muscle Nerve. 2016;53(3):337‐350. doi:10.1002/mus.25008</Citation></Reference><Reference><Citation>Tsairis P. Natural history of brachial plexus neuropathy: report on 99 patients. Arch Neurol. 1972;27(2):109. doi:10.1001/archneur.1972.00490140013004</Citation></Reference><Reference><Citation>Tonali P, Uncini A, Di Pasqua PG. So‐called neuralgic amyotrophy: clinical features and long term follow‐up. Ital J Neurol Sci. 1983;4(4):431‐437. doi:10.1007/BF02125623</Citation></Reference><Reference><Citation>van Alfen N, van Engelen BG, Hughes RA. Treatment for idiopathic and hereditary neuralgic amyotrophy (brachial neuritis). Cochrane Database Syst Rev. 2009;2009(3):CD006976. doi:10.1002/14651858.cd006976.pub2</Citation></Reference><Reference><Citation>Kombe Kombe AJ, Xie J, Zahid A, et al. Detection of circulating VZV‐glycoprotein E‐specific antibodies by chemiluminescent immunoassay (CLIA) for varicella‐zoster diagnosis. Pathog Basel Switz. 2022;11(1):66. doi:10.3390/pathogens11010066</Citation></Reference><Reference><Citation>Parsonage MJ, Turner JWA. Neuralgic amyotrophy; the shoulder‐girdle syndrome. Lancet Lond Engl. 1948;1(6513):973‐978. doi:10.1016/s0140-6736(48)90611-4</Citation></Reference><Reference><Citation>Ripellino P, Lascano AM, Scheidegger O, et al. Neuropathies related to hepatitis E virus infection: a prospective, matched case–control study. Eur J Neurol. 2023;31(1):e16030. doi:10.1111/ene.16030</Citation></Reference><Reference><Citation>Ripellino P, Pasi E, Melli G, et al. Neurologic complications of acute hepatitis E virus infection. Neurol Neuroimmunol Neuroinflammation. 2020;7(1):e643. doi:10.1212/NXI.0000000000000643</Citation></Reference><Reference><Citation>van Eijk JJJ, Madden RG, van der Eijk AA. Neuralgic amyotrophy and hepatitis E virus infection. Neurology. 2014;82(6):498‐503.</Citation></Reference><Reference><Citation>Wendling D, Sevrin P, Bouchaud‐Chabot A. Parsonage–Turner syndrome revealing Lyme borreliosis. Joint Bone Spine. 2009;76(2):202‐204.</Citation></Reference><Reference><Citation>Gorson KC, Kolb DA, Marks DS, Hayes MT, Baquis GD. Acute brachial diplegia due to Lyme disease. Neurologist. 2011;17(1):24‐27. doi:10.1097/NRL.0b013e31820038cd</Citation></Reference><Reference><Citation>Drozdowski W, Baniukiewicz E. Neuralgic amyotrophy as a manifestation of infectious mononucleosis. J Neurol. 2002;249(11):1605‐1607. doi:10.1007/s00415-002-0868-0</Citation></Reference><Reference><Citation>Janes SEJ, Whitehouse WP. Brachial neuritis following infection with Epstein–Barr virus. Eur J Paediatr Neurol. 2003;7(6):413‐415. doi:10.1016/j.ejpn.2003.08.006</Citation></Reference><Reference><Citation>Tsao BE, Avery R, Shields RW. Neuralgic amyotrophy precipitated by Epstein–Barr virus. Neurology. 2004;62(7):1234‐1235. doi:10.1212/01.wnl.0000118282.17433.31</Citation></Reference><Reference><Citation>Pellas F, Olivares JP, Zandotti C, Delarque A. Neuralgic amyotrophy after parvovirus B19 infection. Lancet. 1993;342(8869):503‐504. doi:10.1016/0140-6736(93)91635-y</Citation></Reference><Reference><Citation>Puechal X, Hilliquin P, Kahan A, Menkes CJ. Neuralgic amyotrophy and polyarthritis caused by parvovirus B19 infection. Ann Rheum Dis. 1998;57(4):262‐263. doi:10.1136/ard.57.4.262</Citation></Reference><Reference><Citation>Staud R, Davidson RA, Corman LC. Brachial plexitis in a patient with acute parvovirus B19 infection. Br J Rheumatol. 1995;34(5):480‐481. doi:10.1093/rheumatology/34.5.480</Citation></Reference><Reference><Citation>Walsh KJ, Armstrong RD, Turner AM. Brachial plexus neuropathy associated with human parvovirus infection. BMJ. 1988;296(6626):896. doi:10.1136/bmj.296.6626.896</Citation></Reference><Reference><Citation>Gariani K, Magistris MR, Nendaz MR. Parsonage–Turner syndrome rather than zoster neuritis? Case Rep Neurol. 2011;3(2):165‐171. doi:10.1159/000330571</Citation></Reference><Reference><Citation>Hoque R, Schwendimann RN, Liendo C, Chesson AL. Brachial neuritis with bilateral diaphragmatic paralysis following herpes zoster: a case report. J Clin Neuromuscul Dis. 2008;9(4):402‐406. doi:10.1097/CND.0b013e318175a5ca</Citation></Reference><Reference><Citation>Lee S, Tsukasaki H, Yamauchi T. Visceral disseminated varicella zoster virus infection with brachial plexus neuritis detected by fluorodeoxyglucose positron emission tomography and computed tomography. J Infect Chemother off J Jpn Soc Chemother. 2019;25(7):556‐558. doi:10.1016/j.jiac.2019.02.015</Citation></Reference><Reference><Citation>Skripuletz T, Pars K, Schulte A. Varicella zoster virus infections in neurological patients: a clinical study. BMC Infect Dis. 2018;18(1):238. doi:10.1186/s12879-018-3137-2</Citation></Reference><Reference><Citation>Vanpee D, Laloux P, Gillet JB, Esselinckx W. Viral brachial neuritis in emergency medicine. J Emerg Med. 2000;18(2):177‐179. doi:10.1016/s0736-4679(99)00189-4</Citation></Reference><Reference><Citation>Sundkvist T. Cytomegalovirus infection complicated by neuralgic amyotrophy. N Engl J Med. 1983;308(8):461. doi:10.1056/NEJM198302243080819</Citation></Reference><Reference><Citation>Scanvion Q, Morell‐Dubois S. Neuralgic amyotrophy triggered by cytomegalovirus: to be aware of this clinical diagnosis. Neurocase. 2022;28(3):320‐322. doi:10.1080/13554794.2022.2085118</Citation></Reference><Reference><Citation>Stek CJ, van Eijk JJJ, Jacobs BC. Neuralgic amyotrophy associated with Bartonella henselae infection. J Neurol Neurosurg Psychiatry. 2011;82(6):707‐708. doi:10.1136/jnnp.2009.191940</Citation></Reference><Reference><Citation>Dietmann A, Colin‐Benoit E, Tinkhauser G, Meinel TR, Scheidegger O. Pearls and oysters: bilateral mononeuropathic neuralgic amyotrophy triggered by Bartonella henselae infection responsive to immunoglobulin. Neurology. 2022;98(14):597‐600. doi:10.1212/wnl.0000000000200014</Citation></Reference><Reference><Citation>Calabrese LH, Proffitt MR, Levin KH, Yen‐Lieberman B, Starkey C. Acute infection with the human immunodeficiency virus (HIV) associated with acute brachial neuritis and exanthematous rash. Ann Intern Med. 1987;107(6):849‐851. doi:10.7326/0003-4819-107-6-849</Citation></Reference><Reference><Citation>Finney KA, David L. Brachial plexus neuritis in the context of acute HIV seroconversion illness: a case report. Int J STD AIDS. 2012;23(2):143‐144. doi:10.1258/ijsa.2011.011176</Citation></Reference><Reference><Citation>Cornea A, Lata I, Simu M, Rosca EC. Parsonage–Turner syndrome following SARS‐CoV‐2 infection: a systematic review. Biomedicine. 2023;11(3):837. doi:10.3390/biomedicines11030837</Citation></Reference><Reference><Citation>Ameer MZ, Haiy AU, Bajwa MH, et al. Association of Parsonage–Turner syndrome with COVID‐19 infection and vaccination: a systematic review. J Int Med Res. 2023;51(7):3000605231187939. doi:10.1177/03000605231187939</Citation></Reference><Reference><Citation>Noseda R, Ripellino P, Ghidossi S, Bertoli R, Ceschi A. Reporting of acute inflammatory neuropathies with COVID‐19 vaccines: subgroup disproportionality analyses in vigibase. Vaccine. 2021;9(9):1022. doi:10.3390/vaccines9091022</Citation></Reference><Reference><Citation>IJspeert J, Janssen RMJ, van Alfen N. Neuralgic amyotrophy. Curr Opin Neurol. 2021;34(5):605‐612.</Citation></Reference><Reference><Citation>van Eijk JJJ, Dalton HR, Ripellino P, et al. Clinical phenotype and outcome of hepatitis E virus‐associated neuralgic amyotrophy. Neurology. 2017;89(9):909‐917. doi:10.1212/WNL.0000000000004297</Citation></Reference></ReferenceList></PubmedData></PubmedArticle>